NEW HOPE: A NEW CLINICALLY EFFECTIVE INGESTIBLE PLANT-BASED LIPIDS TREATMENT FOR CHRONIC DIABETIC WOUNDS AND ULCERS

Global Wound Care Congress

September 12-13, 2016 San Antonio, USA

Brian Scott Peskin

Peskin Pharmaceuticals, USA

Keynote: J Nurs Care

Abstract :

Clinicians all know of the unmet need for a new solution to chronic wounds; in particular, Diabetic Foot Ulcers (DFUs). They present the most challenge to even the best wound care specialists because of the significant added complications of diabetes. Their 50% recurrence rate (after 3 years) and 42% 5-year mortality rate exemplify the underlying causes arenâ�?�?t sufficiently treated and solved. Genetic research offers great promise, but an effective solution is needed today. This presentation will utilize a physiologic approach for advancing healing of all wounds; in particular, the most difficult to heal DFUs. Interdisciplinary discoveries will be explored and integrated into a powerful, new physiologic approach for healing diabetic wounds/ulcers. Neurropathy and ischemia are primary underlying risk factors for diabetic ulcers. Discoveries in cardiology are presented and utilized because more than 50% of patients have microvascular or macrovascular complications. Discoveries in oncology are utilized because cancer is now considered a â�?�?wound that doesnâ�?�?t heal.â�? Utilizing state-of-the art interdisciplinary translational science, the solution is completely epigenetic, easy to clinically implement, and applicable and complementary to all patients regardless of particular underlying etiology or existing treatment. Participants will learn how to modulate key eiconsanoids with correct plant-based lipids to significantly speed wound healing: a) increase cellular oxygenation (decreasing hypoxia) via enchanced mitochondrial and cellular efficiency b) decreasing inflammation and increasing blood flow through increased PGE1 & PGI2 c) reducing blood glucose levels d) accelerating underlying tissue repair. Case Studies will be reviewed to support the recommendations.

Biography :

Brian Peskin, is a theoretical research scientist specializing in lipids based pharmacognosy, and CEO of Peskin Pharmaceuticals. His research focuses specifically on physiologically targeted Essential Fatty Acids (EFAs) and their eicosanoid metabolites. Being a translational science expert with a long-term interest in diabetes and its underlying pathophysiology, extensive work in oncology and cardiology preceeded his applications into diabetic foot ulcers. His work is focused on pathways maximizing oxygen delivery and blood flow to the human cell and maximizing tissue functionality. Focus is on supporting and optimizing the patient's natural physiologic processes - not blocking or impeding metabolic pathways.

Email: prof-peskin@peskinpharma.com